Roche's innovative cancer immunology drug has been approved for first-line treatment of a wide range of small cell lung cancers.

The median survival of small cell lung cancer patients in the tae-san chi ® combined chemotherapy group was 12.3 months, compared with 10.3 months for patients in the chemotherapy group. This is the first time that patients with extensive small cell lung cancer have seen a median survival of more than a year. Recently, China's State Drug Administration officially approved Roche's innovative cancer immunology drug Tai Sanqi ® combined chemotherapy for the first-line treatment of a wide range of small cell lung cancer. As the leading researcher in The IMpower133 study, Professor Cheng Ying, Party Secretary of Jilin Cancer Hospital, Vice Chairman of the Chinese Society of Clinical Oncology (CSCO) and Chairman of the CSCO Small Cell Lung Cancer Committee, introduced.
clinical needs are urgent: small cell lung cancer patients 5-year survival rate of only 2%
" small cell lung cancer accounted for about 15% of lung cancer, is a strong aggressive, rapid proliferation of malignant tumors. Professor Cheng Ying said. The prognosis of patients with small cell lung cancer is very poor, and two-thirds of patients have reached a wide range of patients at first sight, i.e. the disease has been detected with distant organ or lymph node metastasis, and the average survival rate is only 2% after diagnosis.
chemotherapy is currently the most common clinical treatment option for widespread small cell lung cancer, but only 20% of patients with large-period small cell lung cancer will have full symptoms after treatment, often quickly and quickly appear drug resistance, 5 years survival rate is very low.
the first breakthrough in 30 years: reduce the risk of death of patients with small cell lung cancer
this time the State Administration of Drug Administration approved the Tai Sanqi ® (Atlizumab) combined chemotherapy for first-line treatment of a wide range of small cell lung cancer, compared with chemotherapy methods, Tai Sanchi ® combined chemotherapy can significantly extend the total survival of patients with small cell lung cancer, reduce the risk of death of patients in the study by 30%.
", "In March 2019, the U.S. FDA approved Tai Shengqi ® small cell lung cancer indication, less than a year, Tai Shengqi ® small cell lung cancer in China was approved, once again witnessed the Chinese government to speed up the review and approval of new drugs, so that Chinese patients can use the latest drugs in sync with Europe and the United States determination and achievements. Zhou Hong, President of Roche Pharmaceuticals China, said: "Small cell lung cancer is the first indication that Tai Sanqi ® approved in China, and we look forward to more indications in The future of Tai Sanqi ®." "
.